Epitan resumes sustained release trial

By Renate Krelle
Tuesday, 06 July, 2004

Melbourne-based EpiTan (ASX:EPT) has resumed its trial of the sustained release implant for tanning drug Melanotan.

The trial is being conducted at Queensland's Clive Berghofer Cancer Research Centre with a new significantly smaller solid injectable. It will be used to determine the optimal dose for the final commercial formulation of Melanotan.

Epitan executive chairman Dr Wayne Millen said the new implant was able to be injected with a 16 gauge needle.

Cartherics and Catalent announce enhanced partnership

To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...

Alliance seeks to boost regional capacity in clinical trials

Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...

Lipid science receives new Australia-led online hub

The Lipid Network launched this month to build links between researchers, clinicians and industry...

Content from other channels on our network

Five potential hubs found for CCUS

Nominations open for TechDiversity Awards

Digital water treatment — real-time data for safe and efficient processes

Key insights from first mandatory sustainability reporting

Vessev launches an electric hydrofoiling network in Tas

NSW Government opens RNA Research and Manufacturing Facility

Siemens launches purpose‍-‍built AI agent for automation engineering

EtherCAT certified cybersecure to IEC 62443

WA Government extends support for lithium industry

Manufacturing-friendly plastic surface destroys viruses on contact

Support at Home showering reclassified as 'clinical care' as part of $3bn investment

Victoria announces "massive" upgrade to one of its busiest hospitals

NSW IRC decision prompts "mixed emotions" from nurses and midwives

Surgical robot expands its scope of procedures

Neuroscientists propose clinical definition for brain fog in menopause